Shares of Quoin Pharmaceuticals, Ltd. (QNRX) rising more than 28% Tuesday morning at $2.42.
The specialty pharmaceutical company today said it is planning to start a second clinical trial to evaluate QRX003 topical lotion in Netherton Syndrome patients.
Netherton syndrome is a rare hereditary disorder characterized by scaling skin, hair anomalies, increased susceptibility to atopic eczema.
The company said that the study will be conducted under Quoin's currently open Investigational New Drug (IND) Application and will assess QRX003 topical lotion in Netherton patients who are currently receiving treatment including systemic therapy for symptomatic relief.
QNRX has traded in the range of $1.65-$194.62 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.